San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Kinnate Biopharma is raising $97,999,937.00 in new funding. Sources indicate as part of senior management Chief Operating Officer, Mark Meltz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kinnate Biopharma

Kinnate Biopharma is driven by the urgency of cancer patients who need more effective therapies. We utilize our deep expertise in structure-based drug discovery, translational research and patient-driven precision medicine, which we refer to as our Kinnate Discovery Engine, to develop targeted therapies. Our lead programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene, or in the FGFR2 and FGFR3 kinase genes. To help move our programs forward, Kinnate has brought together a management team of precision oncology experts, scientific advisors that are thought leaders from experienced precision medicine cancer centers in the United States and world-class investors.

To learn more about Kinnate Biopharma, visit http://www.kinnate.com/

Contact:
Mark Meltz, Chief Operating Officer
858-299-4699
https://www.linkedin.com/in/mark-meltz-3611a636/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved